Skip to main content

Table 2 Summary of immunophenotypic features and MYC rearrangement status

From: Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients

 

Total N (%)

PBL-HIV N (%)

PBL-PT N (%)

PBL-AD N (%)

PBL-IC N (%)

CD10

13/32 (41)

6/14 (43)

1/2 (50)

1/2 (50)

3/10 (30)

CD20

0/60

0/20

0/3

0/4

0/23

CD45

20/40 (50)

6/11 (54)

0/1

0/2

7/18 (39)

CD56

12/37 (32)

4/11 (36)

0/3

1/3 (33)

5/15 (33)

CD79a

13/35 (37)

2/11 (18)

0/1

1/3 (33)

6/13 (46)

CD138

54/58 (93)

15/19

3/3 (100)

4/4 (100)

22/23 (96)

MUM1

22/24 (92)

8/8 (100)

2/2 (100)

3/4 (75)

7/8 (88)

MYC

13/13 (100)

7/7 (100)

1/1 (100)

0/0 (0)

4/4 (100)

Ki-67 (% median)

90

87.5

97.5

90

80

EBER (ISH)

40/57 (70)

19/19 (100)*

1/3 (33)

2/4 (50)

12/22 (55)

MYC rearrangement (FISH)

10/15 (67)

5/7 (71)**

1/1 (100)

NA

3/6 (50)

  1. PBL plasmablastic lymphoma, HIV human immunodeficiency virus, PT post-transplant, AD autoimmune disease, IC immunocompetent, EBER Epstein- Barr virus-encoded RNA, ISH in situ hybridization; FISH fluorescence in situ hybridization, NA not available
  2. *p = <0.001 (PBL-HIV vs. others); **p = 0.323 (PBL-HIV vs. others)